STOCKS TELEGRAPH

Tag: US Patent and Trademark Office

  • Bio-Path Holdings (NASDAQ: BPTH) Stock Skyrockets After Receiving Patent For Prexigebersen

    Bio-Path Holdings (NASDAQ: BPTH) Stock Skyrockets After Receiving Patent For Prexigebersen

    Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced today that its lead product candidate, prexigebersen, in combination with front line cytidine analogues or Bcr-Abl tyrosine kinase inhibitors, has received the Notice of Allowance from the US Patent and Trademark office.

    US Patent and Trademark Office issued a Notice of Allowance to those candidates which USPTO believes that they are qualified for a patent. Before receiving the patent any candidate developed by the biotech companies is considered ‘Patent Pending’.

    Bio-Path Holdings’ prexigebersen is used to treat different types of cancers in combination with front-line therapies. Prexigebersen is a liposomal formulation holding the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

    The new patent labeled ‘Combination Therapy with Liposomal Antisense Oligonucleotides’ will enable the Bio-Path to use Prexigebersen for the treatment of cancer. This is the greatest achievement for the company as it strengthened its position in the market. Peter Nielsen, President, and CEO of Bio-Path said that this new patent not only protects the company’s core product portfolio but also provides protection in combination with established front-line therapies.

    Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares were trading up 25.18% at $5.12 at the time of writing on Thursday. It has a trading volume of 11.44 million as compared to the average volume of 161.74K. Bio-Path Holdings, Inc. (NASDAQ: BPTH) share price went from a low point of around $2.92 to briefly over $12.86 in the past 52 weeks. BPTH market cap has remained high, hitting $15.34 M at the time of writing.

    The biotechnology company is currently engaged in a Phase 2 clinical trial of prexigebersen along with decitabine to treat acute myeloid Leukemia (AML). This new patent it has received for the unique combination by USPTO will secure its ongoing trial and also provide aid to the company to bring new treatment options to patients with AML.

     

  • Blonder Tongue Receives U.S. Patent Grant For DMM Series Of Products

    Blonder Tongue Laboratories, Inc. (AMEX: BDR) has announced that the US Patent and Trademark Office has granted the company a patent no. US10,805,660, for certain technologies within the DOCSIS Data (DMM) series of products of Blonder Tongue.

    Blonder Tongue’s DMM series of products are currently being installed at various enterprise locations such as healthcare, sports venues, educational and financial institutions by Telecommunications, cable, television, and IP market distribution companies to receive, process, and distribute data, video, and audio content.

    The 660 patented technology of the company is being used to solve the service operator issues relating to the ability to simultaneously deliver traditional live TV entertainment service along with on-demand-based Over-The-Top (OTT) TV entertainment service, wireline-based data, and telephony services. This technology is also used to deliver wireless-based data and telephony services.

    Furthermore, Blonder Tongue Laboratories not only solve the problems related to concurrency but also provide a cleaner and more secure solutions. Its technology is based on the major hospitality brands’ standards for separable video, telephony, and data service delivery.

    Blonder Tongue Laboratories, Inc. (AMEX: BDR) shares were trading up 34.04% at $1.50 at the time of writing on Tuesday. Blonder Tongue Laboratories Inc. (AMEX: BDR) share price went from a low point around $0.38 to briefly over $3.80 in the past 52 weeks, though shares have since pulled back to $1.50. It has moved up 294.74% from its 52-weeks low and moved down -60.53% from its 52-weeks high. BDR market cap has remained high, hitting $13.22M at the time of writing.

    Blonder Laboratories earlier revealed that it has received the patent US10,785,829, for certain technologies within Blonder Tongue’s NeXgen Gateway (NXG) video delivery platform. from the US Patent and Trademark office.